Aurobindo Pharma to host JP Morgan analyst meet in Hyderabad

0 min read | Published on 21 Sept 2026, 04:19 PM |Updated on 21 Sept 2026, 04:21 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Aurobindo Pharma schedules investor meet for September 24, 2026
Session is part of JP Morgan Healthcare Trip in Hyderabad
Meeting runs from 2:30 pm to 3:30 pm in group format
No UPSI to be discussed during the interaction

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma Limited announced that its officials will participate in an investor and analyst meeting scheduled for September 24, 2026.

The company disclosed the engagement in a filing with stock exchanges on September 21, 2026. The interaction is part of the JP Morgan Healthcare Trip - Hyderabad and will take place in a group format.

Meeting Details

The session is scheduled for 2:30 pm to 3:30 pm at a venue in Hyderabad. The company noted that the schedule remains subject to change based on exigencies from either the investor or the company side.

Date	Time	Event Name	Type	Location
September 24, 2026	2:30 pm to 3:30 pm	JP Morgan Healthcare Trip - Hyderabad	Group meeting	Hyderabad

Regulatory Disclosure

Aurobindo Pharma stated that no unpublished price-sensitive information (UPSI) is intended to be discussed during the interactions. B. Adi Reddy, Company Secretary, signed the disclosure.

Historical Stock Returns for Aurobindo Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.19%	+2.00%	+4.16%	+35.02%	+51.78%	0.0%

Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How might Aurobindo Pharma's strategic updates during the JP Morgan Healthcare Trip influence its valuation multiples relative to other Indian generic drug manufacturers?

What specific pipeline developments or capacity expansion plans in the US and European markets are analysts likely to probe given the current regulatory environment?

Could the group meeting format signal a shift in investor sentiment regarding Aurobindo's debt reduction progress or margin improvement trajectory?

Aurobindo Pharma

View Company Insights

View All News

Aurobindo Pharma gets USFDA approval for Beclomethasone HFA aerosol

1 min read | Published on 15 Sept 2026, 01:18 PM |Updated on 15 Sept 2026, 01:30 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Aurobindo Pharma receives USFDA final approval for Beclomethasone HFA Inhalation Aerosol 40 mcg and 80 mcg on September 15, 2026
This is the company's first metered-dose inhaler (MDI) product, a generic equivalent of Teva's QVAR®
The product will be manufactured at the company's Raleigh, North Carolina facility owned by Aurolife Pharma LLC
The US market for the approved product is estimated at $301 million for the twelve months ended July 2026
Cumulative USFDA ANDA approvals for Aurobindo Pharma now stand at 596

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma received final approval from the US Food and Drug Administration (USFDA) on September 15, 2026, for Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths. This marks the company's first metered-dose inhaler (MDI) product.

The product is a generic equivalent of QVAR® Inhalation Aerosol, marketed by Teva Branded Pharmaceutical Products R&D LLC. It will be manufactured at Aurobindo Pharma's Raleigh facility in North Carolina, owned by its wholly owned step-down subsidiary Aurolife Pharma LLC.

Product and market details

The following table summarises the key details of the approved product and its market context:

Parameter	Details
Product name	Beclomethasone Dipropionate HFA Inhalation Aerosol
Strengths	40 mcg and 80 mcg
Approval type	USFDA final approval
Approval date	September 15, 2026
Product category	Metered-dose inhaler (MDI)
Reference product	QVAR® Inhalation Aerosol (Teva)
Manufacturing site	Raleigh, North Carolina
US market size	$301 million
Launch status	Expected in upcoming quarters

Significance of the MDI approval

Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older. Its approval positions Aurobindo Pharma in a US market estimated at $301 million for the twelve months ended July 2026, according to IQVIA.

This is the company's first MDI product, representing an entry into the complex respiratory therapies segment of the US generics market. With this approval, Aurobindo Pharma's cumulative USFDA ANDA approvals stand at 596, comprising 571 final approvals and 25 tentative approvals.

What the Numbers Show

The addition of this product strengthens Aurobindo Pharma's portfolio of complex and differentiated products. The company now has 596 cumulative USFDA ANDA approvals, with this new MDI adding to its capabilities in the inhalation segment. The $301 million market size for the approved product and newer versions of the reference product indicates a significant revenue opportunity for the company's first foray into metered-dose inhalers.

Historical Stock Returns for Aurobindo Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.19%	+2.00%	+4.16%	+35.02%	+51.78%	0.0%

How might the entry of Aurobindo Pharma's generic Beclomethasone impact Teva's pricing strategy and market share for QVAR in the US?

What are the projected timelines and potential regulatory hurdles for Aurobindo to expand its MDI portfolio beyond this initial asthma product?

How does the $301 million market size compare to Aurobindo's existing revenue streams, and what percentage of their US generics revenue could this single product realistically capture?

Aurobindo Pharma

View Company Insights

View All News